Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Cibinqo (abrocitinib by Year
Cibinqo (abrocitinib — atopic dermatitis) — Worldwide revenues ($M) ($M)
Pfizer Cibinqo (abrocitinib: $284M in FY2025, up 32.1% from a year earlier.
Where the FY2025 figure comes from
“|| Cibinqo | 284 | 215 | 32% | 32% | 115 | 90 | 28% | 169 | 126 | 35% | 34%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cibinqo (abrocitinib — atopic dermatitis) — Worldwide revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 284 | +32.1% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 215 | +68.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 128 | +2,460.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 5 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-22) ↗ |
Breakdown
What makes up cibinqo (abrocitinib
- Cibinqo (abrocitinib — atopic dermatitis) — U.S. revenues ($M)115 · FY2025
- Cibinqo (abrocitinib — atopic dermatitis) — International revenues ($M)169 · FY2025
- Cibinqo (abrocitinib — atopic dermatitis) — Worldwide reported YoY (%)32.0% · FY2025
- Cibinqo (abrocitinib — atopic dermatitis) — Worldwide operational (constant-currency) YoY (%)32.0% · FY2025
Cite this data
StockData. (2026). Pfizer Cibinqo (abrocitinib ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/cibinqo-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.